There Has Never Been A Better Time To Buy AstraZeneca plc, Volkswagen AG And Carillion plc

AstraZeneca plc (LON: AZN), Volkswagen AG (XETRA: VOW) and Carillion (LON: CLLN) are bargain buys.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

So it’s the new financial year. You can invest up to £15,240 in a stocks & shares ISA. After a rocky few months, global stock markets look cheap as chips. I firmly believe that this is a great time to go shopping for shares. But what will you buy?

Here are three shares that you should buy right now.

AstraZeneca

Five years ago, most investors wouldn’t touch pharmaceutical firm AstraZeneca (LSE: AZN) with a bargepole. With several key drugs tumbling down the patent cliff, and a disappointing drugs pipeline, this company’s share price was plumbing the depths. The heyday of Big Pharma looked to be past.

But chief executive Pascal Soriot has turned round the fortunes of this drugs giant. A focus on world-class research, cutting edge biotechnology, and the development of money-spinning anti-cancer treatments have sparked a revival in profits, and the share price. It’s no surprise that Pfizer recently tried to buy AZ. This is one of the pharmaceutical industry’s most prized assets.

Yet the share price is off its highs, and I think there’s more to come from this dividend dynamo. A 2016 P/E ratio of 14.54 and an income of 4.82% look good value.

Volkswagen

The emissions scandal that has hit Volkswagen (XETRA: VOW) over the past year has sent the share price tumbling. Yet my view is this ‘crisis’ is no worse that what carmaking rival Toyota went through just a few years ago and today Toyota is the most successful car firm in the world, its recall scandal already forgotten.

Anyone who has seen the new Audi A4 and the Volkswagen Passat will know that Volkswagen makes some of the best cars in the world. It doesn’t look like a business that’s going down the tubes.

That’s why I think Volkswagen is currently oversold, and is a strong contrarian buy. A P/E of 9.56, with a dividend yield of 3.99%, means this is a bargain that shouldn’t be missed.

Carillion

Carillion (LSE: CLLN) is one of Britain’s leading building and support service firms, and is highly profitable. It’s set to gain as a resurgent Britain invests more in its infrastructure over the coming years.

It made a net profit of £139m in 2015, and earnings are set to advance further. Yet this is a business going dirt cheap. The 2016 P/E ratio is 8.37, with a dividend yield of 6.79%.

By any measure, these are enticing numbers, and you should buy Carillion both for growth, and for the dividend.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

14.5bn reasons why I think the Legal & General share price is at least 11% undervalued

According to our writer, the Legal & General share price doesn’t appear to reflect the underlying profitability of the business. 

Read more »